Bispecific M&A reaches AstraZeneca; Countdown for Merck's big bid; Biotech buyout in savage times; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Thanks to the short week, we have a lighter edition and fewer stories to recap — but the news is no less interesting, and some might just surprise you.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.